SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...
In this expert perspective from Retina 2026, Sharon Fekrat, MD, FACS, FASRS, discusses a real-world retrospective analysis of the Vestrum Health Retina Database of patients with retinal vein occlusion ...
June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...
Real-world, 12-month results demonstrated efficacy, safety and durability for faricimab as a treatment for retinal vein occlusion, according to a speaker at Retina 2026.In light of faricimab’s ...
Every time your heart beats, it pumps blood through a complex network of blood vessels. These blood vessels, which control blood flow, include arteries, veins, and capillaries. If any of these blood ...
Former Pakistan Prime Minister Imran Khan underwent a brief medical procedure after being diagnosed with retinal vein occlusion (RVO), a serious eye condition that blocks blood flow from the retina.
Retinal vascular occlusion affects the eye, specifically the retina. The retina is the light-sensitive layer of tissue that lines the back of your eye. It’s covered with special cells called rods and ...
New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years. However, many patients require ...
Obstructive sleep apnea (OSA) was associated with a notably higher risk of developing retinal vein occlusion across different demographic groups, with the greatest increase observed in people of ...
– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...
– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results